Use of monoclonal antibody Nimotuzumab and radio-chemotherapy in the treatment of patients with locally advanced head and neck cancer - PL013 N-CRT-CC
Latest Information Update: 16 Oct 2020
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- Acronyms PL013N-CRT-CC
- 08 Mar 2017 New trial record